AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11881630 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 suprastructure modalities (specific types not detailed)
Number of subjects: 18
Study 11881630 — intervention group
Group type: COMPARATOR
Intervention: Clenching without implant support
Number of subjects: 18
Study 11881630 — intervention group
Group type: EXPERIMENTAL
Intervention: Clenching with implant support
Number of subjects: 18
Study 10544835 — intervention group
Group type: EXPERIMENTAL
Intervention: LongoVital (LV)
Number of subjects: 40
Study 7551918 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy followed by surgery
Number of subjects: 0
Study 7551918 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0
Study 7551918 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy combined with preoperative radiation therapy
Number of subjects: 0
Study 7551918 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study 1693711 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine added to beta-blocker
Number of subjects: 471
Study 1693711 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine monotherapy
Number of subjects: 471
Study 471965 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education materials and follow-up visit
Number of subjects: 54
Study 471965 — intervention group
Group type: COMPARATOR
Intervention: Control group (no health education materials)
Number of subjects: 54
Study 471965 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education materials
Number of subjects: 54
Study 31934950 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional microablative CO2 laser treatment
Number of subjects: 40
Study 31134707 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietitian Group (DG) - advised by dietitians in six weekly face-to-face behavioural therapy sessions
Number of subjects: 100
Study 31134707 — intervention group
Group type: COMPARATOR
Intervention: Physician Group (PG) - received standard advice from physicians
Number of subjects: 100
Study 31134707 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietitian Group (DG)
Number of subjects: 100
Study 31134707 — intervention group
Group type: COMPARATOR
Intervention: Physician Group (PG)
Number of subjects: 100
Study 29072977 — intervention group
Group type: EXPERIMENTAL
Intervention: AC followed by Paclitaxel and Trastuzumab
Number of subjects: 407
Study 29072977 — intervention group
Group type: COMPARATOR
Intervention: AC followed by Paclitaxel
Number of subjects: 407
Study 29072977 — intervention group
Group type: EXPERIMENTAL
Intervention: Duke Activity Status Index (DASI) scores
Number of subjects: 407
Study 25814318 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinocembrin 20-150 mg single ascending doses
Number of subjects: 58
Study 25814318 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinocembrin 60 mg multiple doses
Number of subjects: 58
Study 25814318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 23479384 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (week 1: 400 mg/m²; subsequent weeks: 250 mg/m²) plus cisplatin (100 mg/m², day 1) and 5-fluorouracil (1000 mg/m²/day, 24-h infusion, days 1-4)
Number of subjects: 33
Study 21849487 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib-dexamethasone (VD)
Number of subjects: 199
Study 21849487 — intervention group
Group type: COMPARATOR
Intervention: Reduced-dose bortezomib, thalidomide plus dexamethasone (vtD)
Number of subjects: 199
Study 18809176 — intervention group
Group type: EXPERIMENTAL
Intervention: Referential communication tasks; measures of inhibitory control, working memory, and cognitive flexibility
Number of subjects: 0
Study 18809176 — intervention group
Group type: EXPERIMENTAL
Intervention: Speaker's perspective in interpreting instructions
Number of subjects: 0
Study 17156835 — intervention group
Group type: EXPERIMENTAL
Intervention: Fight Cancer with Fitness! (FCF) intervention
Number of subjects: 366
Study 17156835 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 366
Study 15480324 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg/d
Number of subjects: 551
Study 15480324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 551
Study 11709567 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined-modality therapy (CMT) consisting of three cycles of doxorubicin and vinblastine followed by subtotal lymphoid irradiation (STLI)
Number of subjects: 348
Study 11709567 — intervention group
Group type: COMPARATOR
Intervention: Subtotal lymphoid irradiation (STLI)
Number of subjects: 348
Study 9118690 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated extracorporeal circuit
Number of subjects: 14
Study 9118690 — intervention group
Group type: COMPARATOR
Intervention: Noncoated extracorporeal circuit
Number of subjects: 14
Study 9118690 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 14
Study 8441570 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam, 0.4 mg/kg
Number of subjects: 59
Study 8441570 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 59
Study 8441570 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 59
Study 8441570 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam
Number of subjects: 59
Study 8441570 — intervention group
Group type: COMPARATOR
Intervention: Placebo/control group
Number of subjects: 59
Study 2876183 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g calcium per day
Number of subjects: 90
Study 2876183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 31789965 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective ventilation (Low tidal volume of 6 ml/kg predicted body weight during two-lung ventilation and 3 ml/kg predicted body weight during one-lung ventilation with 5 cmH2O positive end-expiratory pressure)
Number of subjects: 29
Study 31789965 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation (Intermediate tidal volume of 10 ml/kg predicted body weight during two-lung ventilation and 5 ml/kg predicted body weight during one-lung ventilation with no positive end-expiratory pressure)
Number of subjects: 29
Study 30413407 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpelisib plus fulvestrant endocrine therapy
Number of subjects: 0
Study 30413407 — intervention group
Group type: COMPARATOR
Intervention: Fulvestrant plus placebo
Number of subjects: 0
Study 25719725 — intervention group
Group type: EXPERIMENTAL
Intervention: Cograft of acellular dermal matrix with autologous split-thickness skin graft (group A)
Number of subjects: 19
Study 25719725 — intervention group
Group type: COMPARATOR
Intervention: Autologous split-thickness skin graft alone (group B)
Number of subjects: 19
Study 22984204 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin-containing quadruple therapy (EBTL group): 40 mg of esomeprazole twice daily, 300 mg of bismuth subcitrate four times daily, 500 mg of tetracycline four times daily, and 500 mg of levofloxacin once daily for 10 days (n = 76)
Number of subjects: 150
Study 22984204 — intervention group
Group type: COMPARATOR
Intervention: High-dose metronidazole-based quadruple therapy (EBTM group): 40 mg of esomeprazole twice daily, 300 mg of bismuth subcitrate four times daily, 500 mg of tetracycline four times daily, and 500 mg of metronidazole four times daily for 10 days (n = 74)
Number of subjects: 150
Study 22984204 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin-containing quadruple therapy (EBTL group)
Number of subjects: 150
Study 22984204 — intervention group
Group type: COMPARATOR
Intervention: High-dose metronidazole-based quadruple therapy (EBTM group)
Number of subjects: 150
Study 22984204 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 150
Study 22073795 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (60 mg elemental iron)
Number of subjects: 148
Study 22073795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 19194499 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine (SP) plus artesunate (AS)
Number of subjects: 191
Study 19194499 — intervention group
Group type: COMPARATOR
Intervention: Sulphadoxine-pyrimethamine (SP) alone
Number of subjects: 191
Study 19194499 — intervention group
Group type: COMPARATOR
Intervention: Double mutant infections
Number of subjects: 191
Study 16814950 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 Gy in 10 fractions
Number of subjects: 0
Study 16814950 — intervention group
Group type: COMPARATOR
Intervention: 8 Gy in 1 fraction
Number of subjects: 0
Study 15046441 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrodiastasis for approximately four months
Number of subjects: 45
Study 15046441 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (historical control group)
Number of subjects: 45
Study 11111188 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant total androgen deprivation using a LHRH analogue (goserelin) plus flutamide for a period of 3 months
Number of subjects: 402
Study 11111188 — intervention group
Group type: COMPARATOR
Intervention: Radical prostatectomy only
Number of subjects: 402
Study 8915150 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphencyprone (DPCP) treatment, 2% solution, applied once a week for at least 3 months, up to 1 year.
Number of subjects: 26
Study 1347854 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (600 mg over 5 days)
Number of subjects: 127
Study 1347854 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine (750 mg then 500 mg 6 h later)
Number of subjects: 127
Study 1347854 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate followed by mefloquine
Number of subjects: 127
Study 1347854 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate
Number of subjects: 127
Study 1347854 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of artesunate and mefloquine
Number of subjects: 127
Study 2859204 — intervention group
Group type: EXPERIMENTAL
Intervention: BW 825C
Number of subjects: 12
Study 2859204 — intervention group
Group type: EXPERIMENTAL
Intervention: Triprolidine (2.5 mg and 5 mg)
Number of subjects: 12
Study 2859204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2957398 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin 0.05% gel
Number of subjects: 268
Study 2957398 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 268
Study 31365710 — intervention group
Group type: EXPERIMENTAL
Intervention: L8020 yogurt
Number of subjects: 23
Study 31365710 — intervention group
Group type: COMPARATOR
Intervention: Placebo yogurt
Number of subjects: 23
Study 28485828 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotomy
Number of subjects: 288
Study 28485828 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 288
Study 25182079 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy (BLT)
Number of subjects: 30
Study 25182079 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 30
Study 23092741 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based nutrition education (n=57)
Number of subjects: 123
Study 23092741 — intervention group
Group type: COMPARATOR
Intervention: In-person nutrition education (n=66)
Number of subjects: 123
Study 23092741 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based nutrition education
Number of subjects: 123
Study 21659439 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic polymer-coated zotarolimus-eluting stent (ZES)
Number of subjects: 58
Study 21659439 — intervention group
Group type: COMPARATOR
Intervention: Fluoropolymer-coated everolimus-eluting stent (EES)
Number of subjects: 58
Study 17764096 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment arm
Number of subjects: 1356
Study 17764096 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 1356
Study 17069543 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 11
Study 17069543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 14625623 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with folate (5-methyl-tetrahydrofolate), vitamin B6, and B12
Number of subjects: 3000
Study 14625623 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with omega-3 fatty acids
Number of subjects: 3000
Study 14625623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3000
Study 11132613 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5-10 mg o.d. (n = 15)
Number of subjects: 60
Study 11132613 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 5-10 mg o.d. (n = 15)
Number of subjects: 60
Study 11132613 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine 4-6 mg o.d. (n = 15)
Number of subjects: 60
Study 11132613 — intervention group
Group type: EXPERIMENTAL
Intervention: Manidipine 10-20 mg o.d. (n = 15)
Number of subjects: 60
Study 9163255 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide-containing suppositories (Massa Estarinum 299)
Number of subjects: 8
Study 9163255 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide Sodium suppositories
Number of subjects: 8
Study 1590228 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (2 mg)
Number of subjects: 25
Study 1590228 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (1 mg)
Number of subjects: 25
Study 1590228 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (2 ml)
Number of subjects: 25
Study 2859054 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruletide (0.6 microgram/kg im)
Number of subjects: 17
Study 2859054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31151437 — intervention group
Group type: EXPERIMENTAL
Intervention: TIME intervention in intervention nursing homes (INH)
Number of subjects: 807
Study 28765003 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine (VAC)
Number of subjects: 268896
Study 28765003 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-vaccinated individuals in vaccinated communities
Number of subjects: 268896
Study 28765003 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention (non-vaccinated communities)
Number of subjects: 268896
Study 25954841 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic device
Number of subjects: 21
Study 25954841 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical disc calculator
Number of subjects: 21
Study 25954841 — intervention group
Group type: COMPARATOR
Intervention: Pen and paper method
Number of subjects: 21
Study 24164697 — intervention group
Group type: EXPERIMENTAL
Intervention: National Exercise Referral Scheme (NERS) for 16 weeks
Number of subjects: 798
Study 24164697 — intervention group
Group type: EXPERIMENTAL
Intervention: National Exercise Referral Scheme (NERS) with participant payments of £1 per session
Number of subjects: 798
Study 24164697 — intervention group
Group type: EXPERIMENTAL
Intervention: National Exercise Referral Scheme (NERS) with participant payments of £2 per session
Number of subjects: 798
Study 24164697 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with mental health risk factors
Number of subjects: 798
Study 24164697 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with chronic heart disease risk factors only
Number of subjects: 798
Study 21485728 — intervention group
Group type: EXPERIMENTAL
Intervention: Alexis wound retractor
Number of subjects: 231
Study 21485728 — intervention group
Group type: COMPARATOR
Intervention: Conventional Doyen retractor
Number of subjects: 231
Study 19289389 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 772
Study 19289389 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean-style diets
Number of subjects: 772
Study 19289389 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dietary fibre intake
Number of subjects: 772
Study 19289389 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased soluble fibre intake
Number of subjects: 772
Study 17348882 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantoplasty (test group)
Number of subjects: 19
Study 17348882 — intervention group
Group type: COMPARATOR
Intervention: Resective surgery (control group)
Number of subjects: 19
Study 17348882 — intervention group
Group type: COMPARATOR
Intervention: Comparison of implantoplasty vs resective surgery
Number of subjects: 19
Study 15190963 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of a monoclonal anti-IL-6 Ab (B-E8)
Number of subjects: 24
Study 15190963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12174332 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor rehabilitation (rehabilitation group, RG)
Number of subjects: 195
Study 12174332 — intervention group
Group type: COMPARATOR
Intervention: Ambulant group (control)
Number of subjects: 195
Study 11477830 — intervention group
Group type: EXPERIMENTAL
Intervention: Acanthopanax Injection (AI) 60-80 ml added to 500 ml of 0.9% normal saline, given intravenously once a day for 14 days
Number of subjects: 60
Study 11477830 — intervention group
Group type: COMPARATOR
Intervention: Control group received 500 ml of dextra-40 given intravenously once a day for 14 days
Number of subjects: 60
Study 11477830 — intervention group
Group type: EXPERIMENTAL
Intervention: Acanthopanax Injection (AI) 10 ml given intravenously once daily for 7 days in rabbit model
Number of subjects: 60
Study 11477830 — intervention group
Group type: COMPARATOR
Intervention: Control group received 10 ml of normal saline given intravenously once daily for 7 days in rabbit model
Number of subjects: 60
Study 8681496 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (2 g x 3 for two weeks)
Number of subjects: 50
Study 8681496 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (300 mg x 3 for two weeks)
Number of subjects: 50
Study 8681496 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone + L-carnitine (300 mg x 3 + 2 g x 3 at the second week)
Number of subjects: 50
Study 8681496 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine (200 mg x 3 for two weeks)
Number of subjects: 50
Study 8681496 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine + L-carnitine (200 mg x 3 + 2 g x 3 at the second week)
Number of subjects: 50
Study 2482304 — intervention group
Group type: EXPERIMENTAL
Intervention: Levorotatory disopyramide (R(‐) DP)
Number of subjects: 0
Study 2482304 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic disopyramide (equimolar mixture of R(‐) DP and S(+) DP)
Number of subjects: 0
Study 2482304 — intervention group
Group type: COMPARATOR
Intervention: Racemic disopyramide (S(+) DP)
Number of subjects: 0
Study 355647 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 17
Study 355647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 355647 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 17
Study 31534062 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 1578
Study 31534062 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1578
Study 30166422 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg controlled-release oral morphine
Number of subjects: 60
Study 30166422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28698334 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly text messages reminding them to test for HIV/STIs
Number of subjects: 600
Study 28698334 — intervention group
Group type: COMPARATOR
Intervention: No reminders
Number of subjects: 600
Study 26504123 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser acupuncture combined with pharmacological therapy (morphine and phenobarbital)
Number of subjects: 28
Study 26504123 — intervention group
Group type: COMPARATOR
Intervention: Control group (pharmacological therapy alone)
Number of subjects: 28
Study 23361468 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided transversus abdominis plane (USG-TAP) block
Number of subjects: 100
Study 23361468 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 21885624 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental (INCR) cycle exercise
Number of subjects: 16
Study 21885624 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity constant work-rate (CWR) cycle exercise
Number of subjects: 16
Study 18835662 — intervention group
Group type: EXPERIMENTAL
Intervention: Compassion meditation (n=33)
Number of subjects: 61
Study 18835662 — intervention group
Group type: COMPARATOR
Intervention: Health discussion control group (n=28)
Number of subjects: 61
Study 17684614 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 72
Study 17684614 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 72
Study 15548314 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) 25 mg base/kg
Number of subjects: 316
Study 15548314 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP) 1.25/25 mg/kg
Number of subjects: 316
Study 15548314 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine (M) 15 mg base/kg
Number of subjects: 316
Study 15548314 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine-artesunate (MA) 15:4 mg/kg
Number of subjects: 316
Study 11171709 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (various compositions, including high carbohydrate meals)
Number of subjects: 21
Study 11171709 — intervention group
Group type: EXPERIMENTAL
Intervention: Anabolic steroids
Number of subjects: 21
Study 11171709 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone
Number of subjects: 21
Study 11171709 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional repletion (dietary regimen with high percentage of calories from fat)
Number of subjects: 21
Study 11171709 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (general)
Number of subjects: 21
Study 11171709 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional repletion
Number of subjects: 21
Study 9627067 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR-plus
Number of subjects: 40